Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood protein map may reveal hidden clues in ovarian cancer treatment

NCT ID NCT07684846

Knowledge-focused Sponsor: University Medical Centre Ljubljana Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This study looks at how proteins in the blood change in women with ovarian cancer as they go through standard treatment. Researchers collected blood samples before surgery, after surgery, and after chemotherapy to see if these protein shifts could give a fuller picture of how the body responds to treatment. The goal is to find new ways to monitor the disease beyond the usual blood tests.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to better ways to monitor ovarian cancer treatment response and detect recurrence earlier.
What could go wrong
This is a small observational study, not a treatment trial. The findings may not translate into clinical practice or benefit patients directly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

33 people

The number who actually took part.

Started

Oct 2021

Finished

Mar 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years. * Histologically confirmed epithelial ovarian cancer or primary peritoneal Müllerian carcinoma. * Undergoing standard treatment including surgery and/or systemic therapy. * Availability of plasma samples collected at one or more predefined treatment timepoints (pre-operative, post-operative, and/or post-chemotherapy). * Availability of corresponding clinical and biomarker data (CA125 and/or HE4). * Written informed consent Exclusion Criteria * Non-epithelial ovarian malignancies. * Insufficient plasma sample volume or inadequate sample quality for proteomic analysis. * Missing essential clinical data required for study analyses. * Withdrawal of informed consent. * Concurrent participation in another study that would prevent interpretation of biomarker analyses.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Epithelial ovarian cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ovarian cancer ovarian carcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ovarian cancer Ovarian cancer recurrent

Contacts and locations

Locations

  • UMC Ljubljana

    Ljubljana, Slovenia

More trials for these conditions

Other studies related to the condition(s) this trial covers.